A Multicenter Investigation with D-FISH BCR/ABL1 Probes

Dewald, Gordon W.; Stallard, Richard E.; Al-Saadi, Abdul; Arnold, Susan; Blough, Ruthann I.; Ceperich, Tina M; Elejalde, B. Rafaël; Fink, Jürgen; Higgins, James V.; Higgins, Rodney R.; Hoeltge, Gerald A.; Hsu, Wei-Tong; Johnson, Eric B.; Kronberger, Diane L; McCorquodale, D.J.; Meisner, Lorraine F.; Micale, Mark A.; Oseth, LeAnn; Payne, J.S.; Schwartz, Stuart; Sheldon, Susan; Sophian, Ardis; Storto, Patrick D.; Tuinen, P van; Wenger, Gail D.; Wiktor, Ann; Willis, L. A.; Yung, Jar-Fee; Zenger‐Hain, Julie

doi:10.1016/s0165-4608(99)00120-x

Cited by 33 publications

(21 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 In acute lymphoblastic leukemia (ALL), where the genetics of the leukemic cells are frequently used for risk stratification and therapeutic decisions, FISH can be used to detect BCR/ABL1, ETV6(TEL)/RUNX1(AML1), and MLL gene rearrangements and hyperdiploidy with extra copies of chromosomes 4, 10, and 17. In acute myeloid leukemia (AML), FISH to detect CBFA2T1(ETO)/RUNX1, PML/RARA, CBFB/MYH11, and MLL gene rearrangements may be performed, as indicated based on the morphological and immunophenotypic findings in the bone marrow.…”

Section: Clinical Indications For Fish Analysismentioning

confidence: 99%

“…The dual-color, dual-fusion BCR(green)/ ABL1(red) probe (D-FISH) set allows for detection of all forms of the BCR/ABL1 fusion (yellow), ie, t(9;22), variant translocations, and cryptic translocations or insertions. 2 The probe set is highly sensitive and consistent, and its technical application and interpretation can be mastered by most laboratories. Initial FISH studies of CML patients yield 85 to 99% of BCR/ABL1-positive nuclei in bone marrow before treatment.…”

Section: Dual-color Dual-fusion Probes: Bcr/abl1mentioning

confidence: 99%

“…Studies indicate that analysis of 500 nuclei with a D-FISH on bone marrow or peripheral blood can detect less than 1% neoplastic cells. 2,17 Strict scoring criteria have been developed for D-FISH to reliably classify individual cells as either normal or abnormal. 2,16,17 With D-FISH, normal cells have two BCR and two ABL1 signals ( Figure 1A).…”

Section: Dual-color Dual-fusion Probes: Bcr/abl1mentioning

confidence: 99%

“…2,17 Strict scoring criteria have been developed for D-FISH to reliably classify individual cells as either normal or abnormal. 2,16,17 With D-FISH, normal cells have two BCR and two ABL1 signals ( Figure 1A). Patients with a conventional t(9;22)(q34;q11.2) have one BCR, one ABL1, and two fused BCR and ABL1 signals ( Figure 1B).…”

Section: Dual-color Dual-fusion Probes: Bcr/abl1mentioning

confidence: 99%

See 3 more Smart Citations

Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders

Wolff

Bagg

Cooley

et al. 2007

The Journal of Molecular Diagnostics

121

View full text Add to dashboard Cite

Fluorescence in situ hybridization (FISH) provides an important adjunct to conventional cytogenetics and molecular studies in the evaluation of chromosome abnormalities associated with hematologic malignancies. FISH employs DNA probes and methods that are generally not Food and Drug Administration-approved, and therefore, their use as analyte-specific reagents involves unique pre-and postanalytical requirements. We provide an overview of the technical parameters influencing a reliable FISH result and encourage laboratories to adopt specific procedures and policies in implementing metaphase and interphase The World Health Organization recent classification of tumors of hematopoietic and lymphoid tissues emphasizes the importance of chromosome abnormalities for accurate diagnosis, appropriate treatment, and monitoring response to therapy.1 In certain scenarios, fluorescence in situ hybridization (FISH) analysis offers one of the most sensitive, specific, and reliable strategies for identifying acquired chromosomal changes associated with hematologic disorders. With the growth in the understanding of the importance of cytogenetic abnormalities associated with these diseases and the availability of commercial FISH probes, this area of clinical laboratory testing is rapidly expanding. Here, we offer guidance for initiating, validating, routinely performing, and reporting FISH studies for hematologic disorders. The recommendations in this article provide detailed assistance for implementing FISH testing and are meant to assist laboratories with complying with existing

show abstract

Section: Clinical Indications For Fish Analysismentioning

confidence: 99%

Section: Dual-color Dual-fusion Probes: Bcr/abl1mentioning

confidence: 99%

Section: Dual-color Dual-fusion Probes: Bcr/abl1mentioning

confidence: 99%

Section: Dual-color Dual-fusion Probes: Bcr/abl1mentioning

confidence: 99%

See 2 more Smart Citations

Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders

Wolff

Bagg

Cooley

et al. 2007

The Journal of Molecular Diagnostics

121

View full text Add to dashboard Cite

show abstract

“…• Fluorescence in situ hybridization can be used to clarify ambiguous or complex rearrangements, or to assist in clarifying rearrangements when morphology is poor (for example, to confirm the involvement of mixed lineage leukemia in an 11q23 rearrangement) • Interphase fish can be useful at follow-up to detect specific structural abnormalities such as t(9;22) 8 . Analyze a minimum of 200 nuclei.…”

Section: Translocation and Deletion Detectionmentioning

confidence: 99%

Canadian College of Medical Geneticists Guidelines for the Indications, Analysis, and Reporting of Cancer Specimens

et al. 2011

View full text Add to dashboard Cite

The Canadian College of Medical Geneticists (ccmg) is a national organization of medical and laboratory geneticists. The mission of the ccmg is to establish and maintain high-quality professional and ethical standards for medical genetics services in Canada and to help to ensure that service of the highest quality is delivered to the Canadian public. Cancer cytogenetics is one of the sections of practice of the ccmg. The ccmg Cytogenetic Committee has, therefore, put forward guidelines to provide oncologists and ccmg cytogeneticists with a comprehensive review of the cytogenetic diagnostic tests that are recommended as a minimum standard of care for tumours of hematopoietic and lymphoid tissues and for tumours of soft tissue and bone. The guidelines were approved by the ccmg board of directors in June 2010.

show abstract

Analytic Procedures

2016

Cytogenetic Laboratory Management

View full text Add to dashboard Cite

A Multicenter Investigation with D-FISH BCR/ABL1 Probes

Cited by 33 publications

References 7 publications

Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders

Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders

Canadian College of Medical Geneticists Guidelines for the Indications, Analysis, and Reporting of Cancer Specimens

Analytic Procedures

Contact Info

Product

Resources

About